Optimizing anti-TNF treatment in inflammatory bowel disease
作者： Paul Rutgeerts , Gert van Assche , Séverine Vermeire
DOI: 10.1053/J.GASTRO.2004.02.070
关键词:
摘要: … We discuss the present state of the use of infliximab in inflammatory bowel diseases. The indications for infliximab are summarized in Table 1 and contraindications are summarized in …
gastrojournal.org
core.ac.uk
elsevier.com
cghjournal.org 参考文章(104)
Emma J. Breese, Colin A. Michie, Stuart W. Nicholls, Simon H. Murch, Christopher B. Williams, Paola Domizio, John A. Walker-Smith, Thomas T. Macdonald, Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease Gastroenterology. ,vol. 106, pp. 1455- 1466 ,(1994) , 10.1016/0016-5085(94)90398-0
T Ten Hove, C Van Montfrans, MP Peppelenbosch, SJH Van Deventer, Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease Gut. ,vol. 50, pp. 206- 211 ,(2002) , 10.1136/GUT.50.2.206
Edouard Louis, Zein El Ghoul, Severine Vermeire, Sebastien Dall'ozzo, Paul Rutgeerts, Gilles Paintaud, Jacques Belaiche, Martine De Vos, Andre Van Gossum, Jean-Frederic Colombel, Herve Watier, A polymorphism in IgG Fc receptor gene FCGR3A is associated with biological response to infliximab in crohn disease Gastroenterology. ,vol. 124, ,(2003) , 10.1016/S0016-5085(03)80012-4
Eli D. Ehrenpreis, Sunanda V. Kane, Lawrence B. Cohen, Russell D. Cohen, Stephen B. Hanauer, Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial Gastroenterology. ,vol. 117, pp. 1271- 1277 ,(1999) , 10.1016/S0016-5085(99)70276-3
Hendrik M. van Dullemen, Sander J.H. van Deventer, Daan W. Hommes, Hannie A. Bijl, Jaap Jansen, Guido N.J. Tytgat, James Woody, Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology. ,vol. 109, pp. 129- 135 ,(1995) , 10.1016/0016-5085(95)90277-5
J.-M. Gornet, S. Couve, Z. Hassani, J.-C. Delchier, P. Marteau, J. Cosnes, Y. Bouhnik, J.-L. Dupas, R. Modigliani, F. Taillard, M. Lemann, Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study Alimentary Pharmacology & Therapeutics. ,vol. 18, pp. 175- 181 ,(2003) , 10.1046/J.1365-2036.2003.01686.X
Filip Van den Bosch, Elli Kruithof, Martine De Vos, Filip De Keyser, Herman Mielants, Crohn's disease associated with spondyloarthropathy : effect of TNF-α blockade with infliximab on articular symptoms The Lancet. ,vol. 356, pp. 1821- 1822 ,(2000) , 10.1016/S0140-6736(00)03239-6
Severine Vermeire, Maja Noman, Gert Van Assche, Filip Baert, Kristel Van Steen, Nele Esters, Sofie Joossens, Xavier Bossuyt, Paul Rutgeerts, Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. ,vol. 125, pp. 32- 39 ,(2003) , 10.1016/S0016-5085(03)00701-7
Yosuf El-Shabrawi, Josef Hermann, Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. ,vol. 109, pp. 2342- 2346 ,(2002) , 10.1016/S0161-6420(02)01292-7
M. Mortimore, P. R. Gibson, W. S. Selby, G. L. Radford-Smith, T. H. J. Florin, , Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? Internal Medicine Journal. ,vol. 31, pp. 146- 150 ,(2001) , 10.1046/J.1445-5994.2001.00039.X